The ABCSG-18 trial of 3420 postmenopausal, HR-positive breast cancer patients treated with an aromatase inhibitor showed that denosumab 60 mg every six months improved DFS, OS, and bone metastasis-free survival (BMFS) compared to placebo [38]. Here, CYP19A1 is linked to breast carcinoma.